
With over 1.3 billion people, India should, on the face of it, appear an attractive drug market for life science firms. Nonetheless, Lundbeck has decided to cease its operations in the Central Asian country completely.
The company doesn't want to reveal what precisely led to this development.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app